Abstract
INTRODUCTION
As a result of changing lifestyles and aging populations, the prevalence of colorectal cancer (CRC) remains high and accounts for approximately 25% of the world's cancerrelated deaths [1] [2] [3] . Although surgical resection and chemoradiotherapy are the most commonly used clinical options, surgery is not an option for all patients, and longterm chemoradiotherapy can cause adverse side effects, such as drug resistance, recurrence and metastasis [4] [5] [6] [7] . Therefore, the search for novel therapies has attracted worldwide attention.
Natural products, which often have fewer side effects than synthetic drugs, are important in the treatment of many diseases and have a long history of use in China. Therefore, natural products have been studied by many researchers to find better antitumor drugs [8] [9] [10] [11] . Qingjie Fuzheng granules (QFGs) is a traditional Chinese medicine (TCM) formula ( Table 1 ) that consists of a mixture of four herbs (Scutellaria barbata D. Don, malt, Hedyotis diffusa Willd, and Astragalus) that together confer properties of anti-inflammation, antioxidative, antibacterial, immunity enhancement and digestion promotion. QFGs have been widely used and found to be clinically effective in various cancer treatments, including CRC, and have few side effects.
However, the precise mechanisms and molecular signaling pathways involved in the activity of QFGs' anticancer effect have not been reported in the literature.
CRC develops because of a cell growth imbalance caused by excessive proliferation or lack of apoptosis. Eukaryotic cell proliferation is controlled by the cell cycle, which consists of the G0, G1, S, G2 and M phases. In the detection of cell cycle progression, the G1/S transition is one of the main checkpoints [12] . The main regulatory factors in G1/S progression are cyclin D1 and cyclin-dependent kinase 4 (CDK4), which can form complexes to regulate this progress [13] [14] [15] . A CDK inhibitor, p21, can change the function of CDK-cyclin complexes by binding to them and then suppressing cell proliferation [16] . Normal cell apoptosis can eliminate surplus, redundant, and aberrant cells in animals, so it is essential for normal tissue maintenance. Disorders in this process trigger many diseases, including CRC [17] [18] [19] . The pathways involved in the apoptotic process are the mitochondria-dependent pathway, also called the intrinsic apoptosis pathway, and the death receptor-mediated apoptosis pathway [20] . The former is modulated by the Bax (proapoptotic) and Bcl-2 (anti-apoptotic) family proteins [21] , which control the release of apoptotic correlation factors, such as cytochrome C (Cyt C) [22] . When intracellular damage occurs, mitochondria-dependent apoptosis is triggered. Then, Cyt C, together with Apaf-1 and caspase-9, cleaves caspase-3 [23] . Receptor-mediated apoptosis originates from outside the cell, with the binding of the Fas ligand (termed FasL or CD95L) to the Fas receptor (termed CD95). Once the death receptor pathway is successfully activated, the Fas-associated death domain and caspase-8 will accumulate, and caspase-8 will be cleaved. Then, caspase-8 cleaves caspase-3, which generates the activated form of caspase-3 that serves as the ultimate activator of apoptosis [24] . Therefore, one of the key approaches in the development of antitumor drugs is to promote apoptosis and inhibit tumor cell proliferation, two processes that typically promote cancer growth. There are multiple signaling pathways that regulate cancer growth, including the PI3K/AKT and ERK signaling pathways, and abnormal activation of these signaling pathways can lead to irregular expression of these factors.
The aim of this study is to better understand the mechanism underlying the potential anticancer effect of QFGs by investigating their biological function using the human CRC cell variants HCT-116 and HCT-8. Our results showed that QFGs inhibit proliferation and increase apoptosis in HCT-116 and HCT-8 cells by inactivating the PI3K/AKT and ERK pathways.
MATERIALS AND METHODS

Cell culture
The human colon carcinoma HCT-8 and HCT-116 cell lines were purchased from the American Type Culture Collection. The two cell lines were cultured in Roswell Park Memorial Institute-1640 medium (C11875500BT; Life Technologies Corp. Grand Island, United States) containing 10% fetal bovine serum, 1% penicillin, and 1% streptomycin, and were grown at 37 °C in 5% CO 2 .
Preparation of QFGs and caspase inhibitors
QFGs were obtained and prepared as previously described [11] . Briefly, QFGs powder was dissolved in 1× PBS (store concentration of QFGs is 200 mg/mL) and stored at 20°C
. Inhibitors of caspase-3/-8/-9 (Z-DEVE-FMK, ab120488; Z-IETD-FMK, ab141382; Z-LEHD-FMK, ab142026, Abcam, CA, United States) were dissolved in DMSO to a concentration of 10 mM and stored at -20 °C.
MTT assays
HCT-8 and HCT-116 cells were placed into 96-well plates (1 × 10 5 cell/well). After 12 h, the cells were treated with different doses of QFGs (0.5, 1 and 2 mg/mL) and grown for 24 h, or the cells were treated with a designated dose of QFGs (2 mg/mL) in combination with inhibitors of caspase-3 (Z-DEVE-FMK), caspase-8 (Z-IETD-FMK), and caspase-9 (Z-LEHD-FMK) at a concentration of 10 μmol/L each and then incubated for 24 h. Then, MTT (0.5 mg/mL) was added to each well (100 μL/well) and incubated for 4 h. Subsequently, all wells were treated with DMSO (100 μL/well). Absorbance at 570 nm in each well was measured by using an ELISA reader (Infinite M200 PRO; Tecan Austria GmbH, Austria).
Lactate dehydrogenase assays
Cells were seeded into 12-well plates (1 × 10 5 cell/well), treated with different dose of QFGs (0.5, 1 and 2 mg/mL) and grown for 24 h. Then, a lactate dehydrogenase (LDH) release assay kit (Beyotime, Shanghai, China) was used to determine the LDH activity according to the kit's manual. 
Colony formation assays
After treatment with different concentrations of QFGs (0.5, 1, and 2 mg/mL) for 24 h, a colony formation assay was performed as described previously [11] .
Hoechst 33258 staining
QFGs and 10 μmol/L caspase inhibitors (Z-DEVE-FMK, Z-IETD-FMK, Z-LEHD-FMK) were added to the cells and grown for 24 h. Subsequently, 4% paraformaldehyde was used to fix the cells for 15 min. Then, 4% paraformaldehyde was removed and 1× PBS was used to rinse the cells three times. Then, Hoechst 33258 (c0003; Beyotime, Shanghai, China) (100 μL/well) was added to all wells in the dark for 15 min. The Hoechst 33258 solution was then removed, and 1× PBS was used to rinse the stained cells three times, followed by 1× addition of fresh PBS. An inverted fluorescence microscope (Leica DMI4000B; Leica Camera AG, Solms, Germany) was used to observe and photograph the cells.
Cell cycle assays
Cell cycle was measured in the HCT-8 and HCT-116 cells after treatment with the indicated concentrations of QFGs (0.5, 1 and 2 mg/mL). Cell cycle progression was estimated by using a propidium iodide (PI) kit (KGA512; KeyGen Biotech, Nanjing, China) and fluorescence activated cell sorting according to the manufacturer's instructions.
Annexin V-FITC/PI staining flow cytometry assays
Cells were seeded into 6-well plates (1.5 × 10 5 cell/well), treated with different doses of QFGs (05, 1 and 2 mg/mL) and grown for 24 h. Then, cells were stained by using an Annexin V/PI kit (KGA108; KeyGen BioTech, Nanjing, China) according to the kit's manual. Annexin V-positivity and PI-negativity (lower-right quadrant) represented early apoptotic cells, whereas Annexin V-positivity and PI-positivity (upper-right quadrant) represented late apoptotic cells.
Caspase activity assays
A caspase activity assay kit (caspase-3, KGA204; caspase-8, KGA304; caspase-9, KGA404; KeyGen BioTech, Nanjing, China) was used to detect the activity of caspases according to the manufacturer's instructions. In brief, cell lysates were prepared after the addition of the indicated reaction buffer (provided in the kit) at 37 °C for 4 h in the dark. Absorbance at 405 nm was measured by using an ELISA reader.
Western blot analysis
When CRC cells were treated with different doses of QFGs (05, 1 and 2 mg/mL) for 24 h, a cell lysis buffer containing a cocktail to lyse the cells was added. The bicinchoninic acid assay was used to detect the total protein concentrations, and 50 µg of total protein was used for electroblotting. Five percent skim milk was used to block the NC membranes, and then primary antibodies against Fas, FasL, p-PI3K and p-AKT (ab-110021, ab-15285, ab182651, ab38449; 1:1000, Abcam, CA, United States), p-ERK (sc-16982; 1:1000, Santa Cruz Biotechnology, CA, United States), cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, β-actin, Bcl-2 and Bax (#9662, #4790, #9508, #4967, #4223, #5023; 1:1000, Cell Signaling, Beverly, MA, United States), PI3K, AKT and ERK (13329-1-AP, 10176-2-AP, 16443-1-AP; 1:2000, Proteintech, United States) were added at 4 °C overnight. On the second day, the appropriate HRP-conjugated secondary antibodies (goat anti-mouse IgG secondary antibody, #L3032; goat antirabbit IgG secondary, #L3012; 1:5000, Signalway Antibody, PA, United States) were added and the SuperSignal West Pico Chemiluminescent Substrate was used to detect the signal.
Statistical analysis
One-way ANOVA and SPSS software (version 18.0) were used to analyze all of the data in this study. The data are expressed as the mean ± standard deviation. P < 0.05 indicated statistical significance.
RESULTS
QFGs decreased cell viability and increased cytotoxicity in HCT-116 and HCT-8 cells
The MTT assays and LDH activity assays were used to evaluate the effect of QFGs on the growth of the two cell types. QFGs inhibited cell viability in a dose-dependent manner ( Figure 1A, B) , showing cytotoxicity at 0.5-2.0 mg/mL ( Figure 1C, D) . In Figure 1A and B, cell viability after treatment with QFGs (0.5-2.0 mg/mL, 24 h) decreased by (6.90% ± 1.03%)-(59.70% ± 1.51%) (HCT-116) and (5.56% ± 4.52%)-(49.44% ± 2.47%) (HCT-8) relative to the viability in control cells (P < 0.05). In Figure  1C and D, treatment with QFGs (0.5-2.0 mg/mL, 24 h) increased the LDH activity rate of the cells from 0.52 ± 0.023 to 0.77 ± 0.002 (HCT-116) and from 0.56 ± 0.054 to 0.81 ± 0.044 (HCT-8) relative to that in control cells (P < 0.01). These results proved that QFGs treatment reduced cell viability and increased cytotoxicity in both cell types.
QFGs inhibited the proliferation of HCT-116 and HCT-8 cells by arresting the cell cycle
Cell colony formation assays were used to evaluate the changes in cell growth after treatment with QFGs. As shown in Figure 2A , QFGs dose-dependency inhibited colony formation in HCT-116 and HCT-8 cells. Subsequently, cell cycle assays were used to verify the proliferation-inhibiting effects of QFGs. As shown in Figure 2B -E, the percentages of S phase in HCT-116 cells after treatment with 0, 0.5, 1, and 2 mg/mL QFGs were 44.7% ± 2.77%, 33.45% ± 3.30%, 16.50% ± 2.12%, and 12.86% ± 2.51%, respectively (P < 0.01), and the percentages of S phase in HCT-8 cells after treatment with 0, 0.5, 1, and 2 mg/mL QFGs were 44.55% ± 3.32%, 26.71% ± 2.17%, 25.60% ± 2.19%, and 21.99% ± 3.30%, respectively (P < 0.01). These results suggested that QFGs can inhibit proliferation of both cell types by arresting the cell cycle.
QFGs induced apoptosis of HCT-116 and HCT-8 cells via the mitochondriadependent and death receptor pathways
Hoechst 33258 staining assays were used to evaluate the changes in cell nuclear morphology after treatment with QFGs ( Figure 3A ). The degree of staining was low in untreated cells, but it gradually increased in the other three groups, which indicated a gradual increase in apoptosis. Subsequently, Annexin V-FITC/PI assays were used to verify the apoptosis-inducing effect of QFGs. As shown in Figure 3B , apoptosis percentages in HCT-116 cells after treatment with 0, 0.5, 1, and 2 mg/mL QFGs were 4.07% ± 0.48%, 11.87% ± 0.5%, 12.77% ± 0.67%, and 31.13% ± 0.73%, respectively (P < 0.01), and apoptosis percentages in HCT-8 cells after treatment with 0, 0.5, 1, and 2 mg/mL QFGs were 2.23% ± 0.50%, 9.34% ± 0.69%, 17.19% ± 0.55%, and 33.93% ± 0.93%, respectively (P < 0.01). We also found that QFGs upregulated the expression of cleaved-caspase-3/-8/-9 in both cell types (Figure 3C, D; P < 0.01). At the same time, the caspase activity was measured using a commercial caspase activity assay kit. Identical to the western blot results, the activities of caspase-3/-8/-9 were significantly enhanced by QFGs treatment in both cell types (Figure 3E, F; P < 0.01). These results indicated that QFGs induced apoptosis in the two cell types, and suggested that apoptosis occurred via both the mitochondria-dependent and death receptor-mediated pathways.
To further confirm these findings, various specific caspase inhibitors were used. As shown in Figure 4A , Z-DEVD-FMK, Z-IETD-FMK, and Z-LEHD-FMK markedly inhibited the inhibitory effect of QFGs on cell viability in both cell types (P < 0.05 and 0.01, respectively). In addition, we used the Hoechst 33258 staining assay to detect nuclear morphological changes, and all three caspase inhibitors clearly inhibited the apoptosis-induced effect of QFGs (2 mg/mL) in both cell types ( Figure 4B ). These findings proved that QFGs induced apoptosis via the mitochondria-dependent and death receptor-mediated pathways in both HCT-116 and HCT-8 cells.
QFGs regulated the expressions of survivin, cyclin D1, CDK4, p21, Bax, Bcl-2, Fas, and FasL in HCT-116 and HCT-8 cells During cell cycle regulation, survivin is a key protein that indicates cell cycle progression, and the complex of cyclin D1 and CDK4 directly regulates cell cycle progression [13] . In a previous study, overexpression of this complex has been found to induce cell proliferation, whereas p21 inhibited the effect of the cyclin D1/CDK4 complex [14] . During the regulation of cell apoptosis, Bax and Bcl-2 regulate the mitochondria-dependent pathway [21] , while Fas and FasL activate the death receptor- mediated pathway [24] . We found that QFGs can inhibit proliferation via arrest of the cell cycle in HCT-116 and HCT-8 cells. We used western blotting to test the protein expression levels of survivin, cyclin D1, CDK4, and p21 after the cells were treated with QFGs. As shown in Figure 5A and B, we found that QFGs downregulated the expression of survivin, cyclin D1 and CDK4, but upregulated the level of p21 in both cell types (P < 0.05 and 0.01, respectively). Since we found that QFGs induced apoptosis via the mitochondria-dependent and death receptor-mediated pathways in HCT-116 and HCT-8 cells, we used western blotting to test the protein expression levels of Bcl-2, Bax, Fas, and FasL after the cells were treated with QFGs. As shown in Figure 5C and D, we found that QFGs decreased the expression of Bcl-2 but promoted the expression of Bax, Fas, and FasL in both cell types (P < 0.05 and 0.01, respectively). Briefly, these findings suggest that QFGs inhibit proliferation via cell cycle arrest and induce apoptosis via the mitochondria-dependent and death receptor-mediated pathways in HCT-116 and HCT-8 cells.
QFGs suppressed the PI3K/AKT and ERK signaling pathways in HCT-116 and HCT-8 cells
Cancer occurrence and progression are highly associated with the regulation of multiple signaling pathways, including PI3K/AKT and ERK [25, 26] . To further explore the potential mechanisms underlying the observed anticancer effects of QFGs, we examined the expression of major regulation factors involved in the PI3K/AKT and ERK signaling pathways. As shown in Figure 6A and B, after treatment with QFGs, the ratios of the phosphorylation expression level to the total expression level were significantly downregulated in PI3K, AKT and ERK in both cell types (P < 0.05 and 0.01, respectively), which suggested that the anticancer effect of QFGs on CRC cells occurs via suppression of the PI3K/AKT and ERK signaling pathways.
DISCUSSION
CRC is a deadly disease, primarily due to its high rate of metastasis and recurrence in patients. Multidrug combination therapy and surgical treatment are the main therapeutic methods that can significantly improve patients survival. However, there are many patients with cancer that is drug resistant and recurrent after traditional clinical treatment [27, 28] . Therefore, there is a need to discover new kinds of anticancer drugs, such as herbal products. In recent years, TCM has attracted increasing attention in the field of oncology because of its relative security and long history of application [29] [30] [31] [32] . QFGs are a four-herb TCM formula that consists of Scutellaria barbata D. Don, malt, Hedyotis diffusa Willd, and Astragalus. In the past few years, some studies have proven that Hedyotis diffusa Willd and Scutellaria barbata D. Don are capable of promoting apoptosis and inhibiting growth and angiogenesis in many types of cancer cells, including CRC [33, 34] . Malt could boost the movement of Qi and improve food digestion, and Astragalus is a vital component in many TCM formulas that have been used in clinics to cure many cancer patients, reduce the incidence of complications, and improve the quality of life of cancer patients [35] . However, there are no reports on the underlying signaling pathways and mechanisms involved in QFGs anticancer activity. In this study, we found that QFGs exhibited significant anticancer effects on HCT-116 and HCT-8 cells. The anticancer effect of QFGs is mainly through the inhibition of proliferation and induction of apoptosis, which are mechanisms commonly exploited in tumor therapy. As demonstrated in the current study, QFGs reduced cell viability and increased cytotoxicity in HCT-116 and HCT-8 cells in a dose-dependent manner. Furthermore, we used cell colony formation, nuclear staining, and flow cytometry assays to demonstrate that these effects in HCT-116 and HCT-8 cells resulted from the inhibition of proliferation and induction of apoptosis by QFGs.
Cell proliferation is regulated by the cell cycle, which consists of the G0, G1, S, G2 and M phases. DNA synthesis is completed in S phase, which is responsible for the initiation and completion of DNA replication [20] . Therefore, the G1/S transition is one of the two main checkpoints in the cell cycle. Using a cell cycle assay, we observed that the inhibitory effects of QFGs on HCT-116 and HCT-8 cell proliferation were associated with blocking the G1 to S phase transition. The G1/S process is highly regulated by cyclin D1, which forms complexes with CDK4 [21, 22] . Overexpression of the cyclin D1/CDK4 complex can enhance cell proliferation, whereas p21 can bind to this complex and inhibit its activity [24] . Therefore, the expression of CDK4, cyclin D1 and p21 indicate the proliferation state of HCT-116 and HCT-8 cells to some extent. This study proved that QFGs administration upregulates p21 protein expression while downregulating cyclin D1 and CDK4 protein expression. These results showed that QFGs inhibit HCT-116 and HCT-8 cell proliferation.
Cell apoptosis or programmed death, which is an essential process in a healthy organism, removes surplus and damaged cells [36] [37] [38] . Failure to execute the apoptosis process may lead to various diseases, such as cancer [39] and autoimmune diseases [40] , whereas too much apoptosis may lead to neurodegenerative diseases [41] . There are two pathways involved in apoptosis: the mitochondria-dependent and death receptormediated pathways. The mitochondria-dependent pathway is initiated by caspase-9, and the death receptor pathway is initiated by caspase-8. Both pathways ultimately rely on the activation of caspase-3 [17] [18] [19] . In the mitochondria-dependent apoptosis pathway, mitochondrial dysfunction directly leads to the occurrence of apoptosis and is central to the apoptotic pathway [42] . Mitochondrial outer membrane permeabilization (MOMP), an essential event in the mitochondria-mediated apoptosis pathway, causes the transfer of Cyt C and other apoptotic proteins from the mitochondria into the cytosol, which leads to caspase activation and apoptosis [43] . Caspases are the key proteins in the regulation of cell apoptosis. During mitochondria-mediated apoptosis, caspase-3 is an important activator that can be cleaved by its upstream initiators, such as caspase-9. The present study showed that QFGs promoted the activation of both caspase-9 and caspase-3 in HCT-116 and HCT-8 cells. In addition, the process of HCT-116 and HCT-8 cell death induced by QFGs was followed by an increase in the cleavage of caspases-9 and caspase-3, which then promotes the molecular cascade leading to apoptosis. The Bcl-2 protein is the key regulatory protein in mitochondria-dependent apoptosis. Some studies have reported that MOMP occurs when proapoptotic Bax-like proteins form pores in the mitochondria; however, the effect of anti-apoptotic Bcl-2-like members on MOMP is opposite to that of proapoptotic Bax-like proteins on MOMP. Therefore, the ratio of Bax to Bcl-2 is the key to determining cell survival [44, 45] . Our study proved that QFGs administration upregulated Bax protein expression and downregulated Bcl-2 protein expression. These results showed that QFGs induce HCT-116 and HCT-8 cell apoptosis via the mitochondria-dependent pathway.
During the death receptor apoptosis pathway, caspase-3 is also the ultimate activator of apoptosis. Caspase-3 is cleaved by its downstream initiators, such as caspase-8. In this study, we discovered that both caspase-8 and caspase-3 can be cleaved by QFGs in HCT-116 and HCT-8 cells. In addition, as noted earlier, HCT-116 and HCT-8 cell death induced by QFGs was followed by increased cleavage of caspase-8 and caspase-3, which accelerates apoptosis. In this pathway, death signals are transmitted via cell surface receptors that communicate with the FasL/Fas signaling pathway, which is part of the death receptor pathway. After binding to FasL, Fas trimerizes and interacts with Fas-associated protein with a death domain, which contributes to the cleavage of caspase-8 and caspase-10 and leads to activation of downstream effector caspases, including caspase-3, caspase-6 and caspase-7, ultimately causing apoptosis [24] . In this study, we demonstrated that QFGs treatment upregulated FasL and Fas protein expression. These results showed that QFGs induce HCT-116 and HCT-8 cell apoptosis through the extrinsic apoptosis pathway.
To determine if the two classic apoptosis pathways were both involved in this study, we added caspase-3/-8/-9 inhibitors and performed the MTT and Hoechst 33258 staining assays to test cell viability and cell apoptosis once again. We found that all three inhibitors markedly inhibited the inhibitory effect of QFGs on cell viability in CRC cells, and inhibited the apoptosis induced by QFGs. This result verified that QFGs induced apoptosis via the mitochondria-dependent and death receptor apoptosis pathways in HCT-116 and HCT-8 cells, which directly revealed the multitarget inhibitory effects of QFGs on CRC cells.
The pathogenic mechanisms underlying the development of cancer, including CRC, are heterogeneous and regulated by multiple signaling pathways, including PI3K/AKT and ERK [25, 26] . Previous studies have reported that the PI3K/AKT and ERK signaling pathways regulate cell growth, apoptosis and metastasis [46] . As one of the important intracellular signal transduction pathways, PI3K/AKT signaling has been reported to play important roles in cell survival, apoptosis and metastasis [47] . In previous studies, activated AKT existed in CRC tumors, which has been shown to be a poor prognostic factor for CRC patients [48] . Overexpression of downstream factors of AKT may result in the activation of the PI3K signaling pathway [46] . ERK signaling is also an important pathway that highly regulates cell proliferation and apoptosis. ERK is a mitogen-activated protein kinase (MAPK), which can be activated by MAPK kinase kinase (e.g., Raf), MAPK kinase (e.g., MEK), and MAPK (e.g., ERK) [49] . Activation of the ERK pathway regulates the expression of various genes and proteins that mediate cell proliferation and apoptosis. The present study demonstrated that QFGs suppressed the activations of PI3K, AKT and ERK, which showed that the anticancer effect of QFGs acts on CRC cells via the PI3K/AKT and ERK signaling pathways.
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To better understand the mechanism underlying the potential anti-cancer effect of QFGs on the human CRC cell variants HCT-116 and HCT-8.
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To elucidate the effect of QFGs on the biological function of CRC cells, and to investigate this biological function to explore the exact mechanism of QFGs effects on CRC cells.
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First, cell viability and cytotoxicity were measured by performing MTT and LDH assays. We evaluated the role of QFGs in cell proliferation and apoptosis by assessing colony formation using Hoechst 33258. Second, cell cycle and apoptosis levels were measured by fluorescenceactivated cell sorting. The expression levels of survivin, cyclin D1, CDK4, p21, Bax, Bcl-2, Fas, FasL, and cleaved-caspase-3/-8/-9 were measured by performing western blotting and caspase activity assays. Furthermore, inhibitors of caspase-3/-8/-9 were also used to elucidate the exact apoptosis pathway induced by QFGs in cancer cells. Finally, activation of the PI3K/AKT and ERK signaling pathways was examined using the western blot assay to investigate the possible mechanism. < 0.01) and from 0.56 ± 0.054 to 0.81 ± 0.044 (HCT-8; P < 0.01) compared with non-QFGs treatment groups. Additionally, colony formation and Hoechst 33258 staining assays showed that QFGs inhibited proliferation and induced apoptosis in CRC cells. QFGs also increased the expression levels of Bax, Fas, and FasL, decreased the level of Bcl-2, and stimulated the activation of caspase-3/-8/-9, which were revealed by western blot and caspase activity assays. In contrast, upon adding the three caspase inhibitors, the suppression effect of QFGs on cell viability and apoptosis were markedly inhibited. Moreover, QFGs suppressed the phosphorylation levels of PI3K, AKT and ERK.
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These results demonstrated that QFGs inhibit CRC cell proliferation and induce apoptosis by suppressing the PI3K/AKT and ERK signaling pathways. This indicated that QFGs are a potential new therapeutic treatment for CRC and other cancers.
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